体外膜氧合支持下心源性休克患者全身免疫炎症指数与住院死亡率的关系

IF 2.5 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Shixing Li, Hao Wang, Jin Yu, Jingsong Xu, Yan Xu
{"title":"体外膜氧合支持下心源性休克患者全身免疫炎症指数与住院死亡率的关系","authors":"Shixing Li, Hao Wang, Jin Yu, Jingsong Xu, Yan Xu","doi":"10.1016/j.advms.2025.04.002","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The systemic immune-inflammation index (SII) is a useful predictor in cardiovascular diseases. The purpose of this study was to investigate the association of SII with in-hospital mortality in patients with cardiogenic shock (CS) supported with extracorporeal membrane oxygenation (ECMO).</p><p><strong>Patients and methods: </strong>A total of 126 CS patients received ECMO implantation between January 2020 and December 2023. SII was calculated as follows: SII = neutrophil count × platelet count / lymphocyte count at admission. Participants were divided into high or low SII group based on the cut-off value of SII. In-hospital mortality was compared between the groups.</p><p><strong>Results: </strong>The optimal SII cut-off value for predicting in-hospital mortality in CS patients supported with ECMO was 1735.9 (AUC 0.68, p = 0.001). In-hospital mortality was significantly higher in the high SII group compared to the low SII group (59.09% vs. 21.67%, p <0.001). The univariate and multivariate logistic regression analyses had shown that SII and left ventricular ejection fraction (LVEF) were identified as independent predictors of in-hospital mortality in CS patients supported with ECMO (OR: 1.001, 95% CI: 1.000-1.002, p = 0.007 and OR: 0.881, 95% CI: 0.803-0.966, p = 0.007, respectively). SII combined with LVEF offered a superior prognostic capability compared to SII alone (AUC 0.707, v.s. AUC 0.68).</p><p><strong>Conclusion: </strong>We demonstrated that elevated admission SII was independently associated with in-hospital mortality in CS patients supported with ECMO. These findings highlight the potential role of SII as an indicator of mortality risk in this population.</p>","PeriodicalId":7347,"journal":{"name":"Advances in medical sciences","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association of Systemic Immune-Inflammation Index with in-hospital mortality of cardiogenic shock patients supported with extracorporeal membrane oxygenation.\",\"authors\":\"Shixing Li, Hao Wang, Jin Yu, Jingsong Xu, Yan Xu\",\"doi\":\"10.1016/j.advms.2025.04.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>The systemic immune-inflammation index (SII) is a useful predictor in cardiovascular diseases. The purpose of this study was to investigate the association of SII with in-hospital mortality in patients with cardiogenic shock (CS) supported with extracorporeal membrane oxygenation (ECMO).</p><p><strong>Patients and methods: </strong>A total of 126 CS patients received ECMO implantation between January 2020 and December 2023. SII was calculated as follows: SII = neutrophil count × platelet count / lymphocyte count at admission. Participants were divided into high or low SII group based on the cut-off value of SII. In-hospital mortality was compared between the groups.</p><p><strong>Results: </strong>The optimal SII cut-off value for predicting in-hospital mortality in CS patients supported with ECMO was 1735.9 (AUC 0.68, p = 0.001). In-hospital mortality was significantly higher in the high SII group compared to the low SII group (59.09% vs. 21.67%, p <0.001). The univariate and multivariate logistic regression analyses had shown that SII and left ventricular ejection fraction (LVEF) were identified as independent predictors of in-hospital mortality in CS patients supported with ECMO (OR: 1.001, 95% CI: 1.000-1.002, p = 0.007 and OR: 0.881, 95% CI: 0.803-0.966, p = 0.007, respectively). SII combined with LVEF offered a superior prognostic capability compared to SII alone (AUC 0.707, v.s. AUC 0.68).</p><p><strong>Conclusion: </strong>We demonstrated that elevated admission SII was independently associated with in-hospital mortality in CS patients supported with ECMO. These findings highlight the potential role of SII as an indicator of mortality risk in this population.</p>\",\"PeriodicalId\":7347,\"journal\":{\"name\":\"Advances in medical sciences\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-05-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in medical sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.advms.2025.04.002\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in medical sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.advms.2025.04.002","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

目的:全身免疫炎症指数(SII)是心血管疾病的有效预测指标。本研究的目的是探讨SII与体外膜氧合(ECMO)支持的心源性休克(CS)患者住院死亡率的关系。患者和方法:2020年1月至2023年12月,共126例CS患者接受ECMO植入。SII计算公式如下:SII =入院时中性粒细胞计数×血小板计数/淋巴细胞计数。根据SII的临界值将参与者分为高SII组和低SII组。比较两组之间的住院死亡率。结果:预测经ECMO支持的CS患者住院死亡率的最佳SII临界值为1735.9 (AUC 0.68, p = 0.001)。高SII组的住院死亡率明显高于低SII组(59.09% vs. 21.67%, p)结论:我们证明了入院SII升高与ECMO支持下CS患者的住院死亡率独立相关。这些发现强调了SII作为该人群死亡风险指标的潜在作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Association of Systemic Immune-Inflammation Index with in-hospital mortality of cardiogenic shock patients supported with extracorporeal membrane oxygenation.

Purpose: The systemic immune-inflammation index (SII) is a useful predictor in cardiovascular diseases. The purpose of this study was to investigate the association of SII with in-hospital mortality in patients with cardiogenic shock (CS) supported with extracorporeal membrane oxygenation (ECMO).

Patients and methods: A total of 126 CS patients received ECMO implantation between January 2020 and December 2023. SII was calculated as follows: SII = neutrophil count × platelet count / lymphocyte count at admission. Participants were divided into high or low SII group based on the cut-off value of SII. In-hospital mortality was compared between the groups.

Results: The optimal SII cut-off value for predicting in-hospital mortality in CS patients supported with ECMO was 1735.9 (AUC 0.68, p = 0.001). In-hospital mortality was significantly higher in the high SII group compared to the low SII group (59.09% vs. 21.67%, p <0.001). The univariate and multivariate logistic regression analyses had shown that SII and left ventricular ejection fraction (LVEF) were identified as independent predictors of in-hospital mortality in CS patients supported with ECMO (OR: 1.001, 95% CI: 1.000-1.002, p = 0.007 and OR: 0.881, 95% CI: 0.803-0.966, p = 0.007, respectively). SII combined with LVEF offered a superior prognostic capability compared to SII alone (AUC 0.707, v.s. AUC 0.68).

Conclusion: We demonstrated that elevated admission SII was independently associated with in-hospital mortality in CS patients supported with ECMO. These findings highlight the potential role of SII as an indicator of mortality risk in this population.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Advances in medical sciences
Advances in medical sciences 医学-医学:研究与实验
CiteScore
5.00
自引率
0.00%
发文量
53
审稿时长
25 days
期刊介绍: Advances in Medical Sciences is an international, peer-reviewed journal that welcomes original research articles and reviews on current advances in life sciences, preclinical and clinical medicine, and related disciplines. The Journal’s primary aim is to make every effort to contribute to progress in medical sciences. The strive is to bridge laboratory and clinical settings with cutting edge research findings and new developments. Advances in Medical Sciences publishes articles which bring novel insights into diagnostic and molecular imaging, offering essential prior knowledge for diagnosis and treatment indispensable in all areas of medical sciences. It also publishes articles on pathological sciences giving foundation knowledge on the overall study of human diseases. Through its publications Advances in Medical Sciences also stresses the importance of pharmaceutical sciences as a rapidly and ever expanding area of research on drug design, development, action and evaluation contributing significantly to a variety of scientific disciplines. The journal welcomes submissions from the following disciplines: General and internal medicine, Cancer research, Genetics, Endocrinology, Gastroenterology, Cardiology and Cardiovascular Medicine, Immunology and Allergy, Pathology and Forensic Medicine, Cell and molecular Biology, Haematology, Biochemistry, Clinical and Experimental Pathology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信